Pramipexole and gender identity disorder: Expanding the phenotype of hypersexuality in Parkinson's disease

Movement Disorders

Volumn 24, Issue 16, 2009, Pages 2434-2435

  Odiyoor, Mahesh ^a   Kobylecki, Christopher ^a,b   Hackett, Richard J ^a   Silverdale, Monty A ^a   Kellett, Mark W ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE;

ADULT; BRADYKINESIA; CASE REPORT; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GAIT DISORDER; GENDER DYSPHORIA; GENDER IDENTITY DISORDER; HUMAN; HYPERSEXUALITY; LETTER; MALE; MUSCLE RIGIDITY; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; GENDER IDENTITY; HUMANS; MALE; PARKINSON DISEASE; PHENOTYPE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 73949090357     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22848     Document Type: Letter

References (8)

1. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
2. Riley DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol 2002; 25:234-237.
3. Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 2006;12: 392-395.
4. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-1257.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth ed. Washington, DC: American Psychiatric Association, 1995.
6. Tugnet N, Goddard JC, Vickery RM, Khoosal D, Terry TR. Current management of male-to-female gender identity disorder in the UK. Postgrad Med J 2007;83:638-642.
7. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-386.
8. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003;110:1119-1127.